Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inclisiran - Alnylam Pharmaceuticals/Novartis

Next Previous
X
Search
Drug Profile

Inclisiran - Alnylam Pharmaceuticals/Novartis

Alternative Names: ALN-60212; ALN-PCSsc; KJX-839; Leqvio; PCSK9si

Latest Information Update: 02 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Novartis
  • Class Amides; Amino sugars; Antihyperlipidaemics; Cardiovascular therapies; Drug conjugates; Small interfering RNA; Vascular disorder therapies
  • Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia
  • Registered Hyperlipidaemia
  • Phase III Cardiovascular disorders; Coronary artery disease

Most Recent Events

  • 29 Aug 2024 Efficacy data from a phase III V-Mono trial in Hypercholesterolaemia released by Novartis
  • 20 Jun 2024 Novartis completes the phase-III V-Mono trials in Hypercholesterolaemia (Monotherapy) in Colombia, Germany, Hungary, Mexico, the US (SC, Injection) (NCT05763875)
  • 13 May 2024 Phase-III clinical trials in Hyperlipidaemia (In children, In adolescents) (SC), before May 2024 (Novartis pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top